je.st
news
McKesson Corp. Rating Increased to Overweight at Morgan Stanley
2013-10-26 15:45:19| Biotech - Topix.net
The firm currently has a $177.00 price objective on the stock. Morgan Stanley's price target indicates a potential upside of 14.20% from the company's current price.
Tags: rating
increased
corp
morgan
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||